Tazobactum%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin is a broad-spectrum penicillin antibiotic. Tazobactam is a beta-lactamase inhibitor that extends the spectrum of piperacillin to include many beta-lactamase-producing bacteria. It is administered intravenously. ## Primary Indications Piperacillin-tazobactam is indicated for the treatment of moderate to severe infections caused by susceptible strains of microorganisms in the following conditions: * **Complicated intra-abdominal infections** * **Complicated skin and skin structure infections** (including diabetic foot infections) * **Community-acquired pneumonia** * **Nosocomial pneumonia** * **Bacterial infections** in febrile neutropenic patients (in combination with an aminoglycoside) ## Adult Dosing * **Standard Dosing:** 3.375 grams every 6 hours or 4.5 grams every 8 hours IV. * **Severe Infections/Hospital-Acquired Pneumonia:** 4.5 grams every 6 or 8 hours IV. * **Febrile Neutropenia:** Typically 4.5 grams every 6 or 8 hours IV in combination with an aminoglycoside, adjusted based on local protocol. * **Maximum Dose:** Dosing is generally based on piperacillin content; up to 4.5 grams every 6 hours has been used. Specific maximums depend on indication and severity of infection. ## Pediatric Dosing Dosing for pediatric patients depends on age, weight, and severity of infection. Consult specific pediatric guidelines or institutional protocols. A common regimen for children aged 2 months and older is 90-100 mg piperacillin component per kg per dose IV every 6 or 8 hours. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No adjustment needed. * CrCl 20-40 mL/min: Administer 2.25 grams every 6 hours or 3.375 grams every 8 hours. * CrCl < 20 mL/min: Administer 2.25 grams every 8 hours or 3.375 grams every 12 hours. * Consider intermittent hemodialysis or continuous renal replacement therapy adjustments. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation. * History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, fever. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures (rare, particularly with high doses or renal impairment), neutropenia, thrombocytopenia, elevated liver enzymes. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam serum concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the action of neuromuscular blocking agents. * **Warfarin:** May decrease the efficacy of warfarin; monitor INR closely. * **Methotrexate:** May decrease methotrexate clearance; monitor methotrexate levels. * **Aminoglycosides:** In vitro antagonism can occur. However, in clinical practice, combination is often used for synergistic effect in severe infections like febrile neutropenia. Administer separately. ## Monitoring * Renal function (BUN, creatinine) if baseline impairment or concurrently with nephrotoxic agents. * Liver function tests (AST, ALT) periodically. * Complete blood count (CBC) for potential hematologic changes with prolonged therapy. * Signs and symptoms of infection and superinfection. * Monitor for diarrhea, especially *C. difficile*. ## Clinical Pearls * Piperacillin-tazobactam is a common choice for empiric therapy of serious bacterial infections, especially in hospitalized patients. * The 3.375 g and 4.5 g formulations are most common, representing 3 g piperacillin/0.375 g tazobactam and 4 g piperacillin/0.5 g tazobactam respectively. * Ensure adequate hydration to minimize the risk of crystalluria. * Consider patient's history of allergies, especially to penicillins and cephalosporins. *** **Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive drug information resources. Always verify current prescribing information, product monographs, and institutional protocols before initiating or modifying therapy.